Iurlo et al. reported in a study which included 107 patients (40 treated with dasatinib; 36, nilotinib; and 92, imatinib) at a median age of 56 years, although fasting plasma glucose, insulin, C-peptide, and Homeostasis Model Assessment-Insulin Resistance were significantly higher in the nilotinib group than those in the dasatinib and imatinib groups, LDL-C did not differ significantly between the dasatinib and nilotinib groups, which was higher than that in the imatinib group20. This evidence concerns the gene INS and Insulin resistance.